Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8598197 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US10189849 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US8598186 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US9957276 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10189850 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US10927120 | G1 THERAP | CDK inhibitors |
Oct, 2031
(7 years from now) | |
US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US11717523 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
US11529352 | G1 THERAP | Preservation of immune response during chemotherapy regimens |
Jul, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A m...
Dosage: POWDER;INTRAVENOUS